Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA-FFA gastro-resistant capsules in hospitalized patients with confirmed SARS-CoV-2
2020-001396-33Phase 3Unknown
- Sponsor
- SLA Pharma
- Start
- Apr 2020
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing EPA-FFA gastro-resistant capsules (icosapent ethyl) with Placebo (2 arms). Primary endpoint: Proportion of subjects alive and free of respiratory failure at 28 days. Status: unknown.
02
Drugs
omega-3-acid triglycerides
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001396-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001396-33.